Biblio
Digital microfluidic biochips (DMFBs) have become popular in the healthcare industry recently because of its lowcost, high-throughput, and portability. Users can execute the experiments on biochips with high resolution, and the biochips market therefore grows significantly. However, malicious attackers exploit Intellectual Property (IP) piracy and Trojan attacks to gain illegal profits. The conventional approaches present defense mechanisms that target either IP piracy or Trojan attacks. In practical, DMFBs may suffer from the threat of being attacked by these two attacks at the same time. This paper presents a comprehensive security system to protect DMFBs from IP piracy and Trojan attacks. We propose an authentication mechanism to protect IP and detect errors caused by Trojans with CCD cameras. By our security system, we could generate secret keys for authentication and determine whether the bioassay is under the IP piracy and Trojan attacks. Experimental results demonstrate the efficacy of our security system without overhead of the bioassay completion time.
Researchers develop bioassays following rigorous experimentation in the lab that involves considerable fiscal and highly-skilled-person-hour investment. Previous work shows that a bioassay implementation can be reverse engineered by using images or video and control signals of the biochip. Hence, techniques must be devised to protect the intellectual property (IP) rights of the bioassay developer. This study is the first step in this direction and it makes the following contributions: (1) it introduces use of a sieve-valve as a security primitive to obfuscate bioassay implementations; (2) it shows how sieve-valves can be used to obscure biochip building blocks such as multiplexers and mixers; (3) it presents design rules and security metrics to design and measure obfuscated biochips. We assess the cost-security trade-offs associated with this solution and demonstrate practical sieve-valve based obfuscation on real-life biochips.
As digital microfluidic biochips (DMFBs) make the transition to the marketplace for commercial exploitation, security and intellectual property (IP) protection are emerging as important design considerations. Recent studies have shown that DMFBs are vulnerable to reverse engineering aimed at stealing biomolecular protocols (IP theft). The IP piracy of proprietary protocols may lead to significant losses for pharmaceutical and biotech companies. The micro-electrode-dot-array (MEDA) is a next-generation DMFB platform that supports real-time sensing of droplets and has the added advantage of important security protections. However, real-time sensing offers opportunities to an attacker to steal the biochemical IP. We show that the daisychaining of microelectrodes and the use of one-time-programmability in MEDA biochips provides effective bitstream scrambling of biochemical protocols. To examine the strength of this solution, we develop a SAT attack that can unscramble the bitstreams through repeated observations of bioassays executed on the MEDA platform. Based on insights gained from the SAT attack, we propose an advanced defense against IP theft. Simulation results using real-life biomolecular protocols confirm that while the SAT attack is effective for simple instances, our advanced defense can thwart it for realistic MEDA biochips and real-life protocols.
An intelligent recovery evaluation system is presented for objective assessment and performance monitoring of anterior cruciate ligament reconstructed (ACL-R) subjects. The system acquires 3-D kinematics of tibiofemoral joint and electromyography (EMG) data from surrounding muscles during various ambulatory and balance testing activities through wireless body-mounted inertial and EMG sensors, respectively. An integrated feature set is generated based on different features extracted from data collected for each activity. The fuzzy clustering and adaptive neuro-fuzzy inference techniques are applied to these integrated feature sets in order to provide different recovery progress assessment indicators (e.g., current stage of recovery, percentage of recovery progress as compared to healthy group, etc.) for ACL-R subjects. The system was trained and tested on data collected from a group of healthy and ACL-R subjects. For recovery stage identification, the average testing accuracy of the system was found above 95% (95-99%) for ambulatory activities and above 80% (80-84%) for balance testing activities. The overall recovery evaluation performed by the proposed system was found consistent with the assessment made by the physiotherapists using standard subjective/objective scores. The validated system can potentially be used as a decision supporting tool by physiatrists, physiotherapists, and clinicians for quantitative rehabilitation analysis of ACL-R subjects in conjunction with the existing recovery monitoring systems.